将伽马改性肽核酸自组装成有机溶剂混合物中复杂的纳米结构

Executive Industry Relevance

This protocol enables the self-assembly of gamma-modified peptide nucleic acid (γPNA) nanostructures in organic solvent mixtures, addressing a critical gap in nucleic acid nanotechnology for non-aqueous environments. By demonstrating programmable assembly of addressable single-stranded tiles into micron-scale nanofibers, the method supports target validation and mechanistic de-risking in early discovery where aqueous-incompatible assays or screening campaigns require organic solvent compatibility. The inclusion of surfactant-mediated bundling control provides a tunable parameter for optimizing nanostructure morphology, enhancing reproducibility in downstream biophysical or imaging applications.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of nucleic acid-like recognition in organic solvents, supporting target hypothesis testing where traditional aqueous probes fail due to solubility or stability constraints.
• Operational Value: Provides a standardized scaffold for presenting ligands or capturing analytes in solvent conditions relevant to membrane-associated targets or lipid-based assays.

Screening & Assay Development

• Scientific Value: Generates addressable, single-stranded tile arrays with programmable binding domains for multiplexed target engagement in organic media.
• Operational Value: Yields nanostructures with quantifiable width distributions (median 16.3 nm, max >80 nm) enabling calibration of imaging or detection platforms in non-aqueous formats.
• Scientific Value: Demonstrates surfactant-dependent morphology control (e.g., SDS reducing bundling), allowing assay optimization to minimize false signals from aggregation.

Translational & Preclinical Research

• Scientific Value: Facilitates structure-activity studies of γPNA analogs in solvent systems mimicking intracellular or microenvironmental conditions, supporting translational biomarker exploration.
• Operational Value: Enables longitudinal stability assessment of nanostructures under storage conditions (4°C for 12–24 hours post-annealing), informing reagent handling in preclinical workflows.

Pipeline & Workflow Integration

The method fits within early discovery workflows where target engagement must be assessed in organic solvent mixtures, such as lipid-soluble compound screening or membrane protein assays, prior to lead identification.

• Discovery Biology: Supports hypothesis testing via programmable γPNA tile assembly, enabling de-risking of targets that are inaccessible to aqueous nucleic acid probes.
• Screening: Generates reproducible nanofiber templates for presenting capture molecules in solvent conditions compatible with hydrophobic compound libraries.
• Analytics: Provides measurable outputs (nanofiber width, bundling degree, morphology via TIRF/TEM) for comparing assembly conditions and quantifying structural consistency.
• Translational Research: Connects to preclinical continuity by allowing evaluation of γPNA nanostructures in solvent systems relevant to tissue penetration or subcellular localization studies.
• Enterprise Reuse: Establishes a modular, sequence-agnostic platform for γPNA-based nanostructure fabrication, adaptable across multiple targets without re-engineering core assembly logic.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in nanostructure formation through solvent-specific annealing protocols and surfactant titration, reducing mechanistic ambiguity in non-aqueous recognition events.
• Operational Value: Standardized stock preparation (300 μM in water, −20°C storage) and defined annealing cycles (22.5 hours, 90°C to 20°C) ensure reproducibility across sites and teams.
• Strategic Value: Enables go/no-go decisions for targets requiring organic solvent compatibility, reducing late-stage failure risk from assay-context mismatch.
• Portfolio Impact: Supports risk-adjusted prioritization of screening campaigns by providing a validated method to assess target engagement in physiochemically relevant milieus.

Implementation Considerations

• Requires expertise in nucleic acid nanotechnology and solvent handling, particularly for anhydrous DMSO, DMF, and 1,4-dioxane mixtures.
• Depends on access to thermal cyclers with programmable annealing, fluorescence/TIRF microscopes, and TEM for characterization.
• Necessitates standardization of surfactant concentrations (e.g., 5.25 mM or 17.5 mM SDS) to control bundling, as variability directly impacts nanostructure width and morphology.
• Requires adaptation across model systems due to γPNA’s aggregation propensity in organic solvents, necessitating empirical optimization of solvent ratios and annealing profiles.
• Practical limitation: Nanostructure stability is time-sensitive (12–24 hours at 4°C post-annealing), requiring tight coordination between assembly and imaging to avoid degradation or aggregation.

Biopharma FAQs